CAS Number136236-51-6
Synonyms(1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine; (1R)-N-(Prop-2-yn-1-yl)indan-1-amine; (1R)-N-(2-Propyn-1-yl)-1-indanamine; (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; Rasagiline; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine
Molecular FormulaC12H13N1
Molecular Weight171.24
Density1.1±0.1 g/cm3
Boiling Point305.5±30.0 °C at 760 mmHg
Melting Point35-41°C
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 136236-51-6 |
| Catalog No. | 2A-9086540 |
| Chinese Name | 雷沙吉兰 |
| Synonyms | (1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine; (1R)-N-(Prop-2-yn-1-yl)indan-1-amine; (1R)-N-(2-Propyn-1-yl)-1-indanamine; (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; Rasagiline; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine |
| Molecular Formula | C12H13N1 |
| Molecular Weight | 171.24 |
| Density | 1.1±0.1 g/cm3 |
| Boiling Point | 305.5±30.0 °C at 760 mmHg |
| Melting Point | 35-41°C |
| Storage Condition | 2-8°C |
| Application | Rasagiline (AGN1135; TVP1012) is an MAO-B inhibitor that can act on primary Parkinson's disease. |
| HTC | 2921499090 |
| MDL Number | MFCD00866571 |
| SMILES | C#CCNC1CCc2ccccc21 |
| InChI | InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1 |
| InChI Key | RUOKEQAAGRXIBM-GFCCVEGCSA-N |
| MSDS | msds/86540_1_136236_51_6.pdf |
| Bioactivity | Rasagiline(AGN1135;TVP1012) is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. Target: Monoamine Oxidase (MAO)-BRasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD) [1]. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established [2]. Rasagiline has been found to be well tolerated and effective in the treatment of early PD and as adjunctive treatment in motor fluctuations. Whether rasagiline is associated with clinically significant neuroprotection (ie, disease modification) in PD is the subject of ongoing clinical trials [3]. Related Catalog Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase Research Areas >> Neurological Disease References [1]. Leegwater-Kim, J. and E. Bortan, The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging, 2010. 5: p. 149-56. [2]. Weinreb, O., et al., Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol, 2010. 92(3): p. 330-44. [3]. Chen, J.J., D.M. Swope, and K. Dashtipour, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther, 2007. 29(9): p. 1825-49. Chemical & Physical Properties Density 1.1±0.1 g/cm3 Boiling Point 305.5±30.0 °C at 760 mmHg Melting Point 35-41°C Molecular Formula C12H13N Molecular Weight 171.238 Flash Point 146.8±20.0 °C Exact Mass 171.104797 PSA 12.03000 LogP 2.27 Vapour Pressure 0.0±0.6 mmHg at 25°C Index of Refraction 1.577 InChIKey RUOKEQAAGRXIBM-GFCCVEGCSA-N SMILES C#CCNC1CCc2ccccc21 Storage condition 2-8°C |
| Use of | Properties Name Rasagiline Synonym More Synonyms Rasagiline Biological Activity Related Catalog Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase Research Areas >> Neurological Disease References [1]. Leegwater-Kim, J. and E. Bortan, The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging, 2010. 5: p. 149-56. [2]. Weinreb, O., et al., Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol, 2010. 92(3): p. 330-44. [3]. Chen, J.J., D.M. Swope, and K. Dashtipour, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther, 2007. 29(9): p. 1825-49. Chemical & Physical Properties Molecular Formula C12H13N Exact Mass 171.104797 PSA 12.03000 Index of Refraction 1.577 InChIKey RUOKEQAAGRXIBM-GFCCVEGCSA-N |
| Tax Rebate | 9.0% |
| Supervision | None MFN tariff: 6.5% Ordinary tariff: 30.0% |
| Transport Info | Product name: Summary 2921499090 other aromatic monoamines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
| Related Products in Pharmaceutical Intermediates | ||
|---|---|---|
| 3-Carboxyphenylisothiocyanate | 2131-63-7 | 2A-9086504 |
| 4-Carboxyphenylisothiocyanate | 2131-62-6 | 2A-9086506 |
| N-Boc-4-bromoindoline | 885272-46-8 | 2A-9086529 |
| 1-Benzoyl-6-bromo-7-azaindole | 143468-12-6 | 2A-9086535 |
| (R,S)-2-Amino-3-hydroxy-3-methylbutanoicacid | 2280-28-6 | 2A-9086537 |
| (S)-N-(2-Propynyl)-2,3-dihydroinden-1-amine | 185517-74-2 | 2A-9086546 |
| cis-6-Azabicyclo[3.2.0]heptan-7-one | 39155-94-7；39155-95-8 | 2A-9086553 |
| Ethyl(1R,2S)-2-Aminocyclopentanecarboxylate | 197916-36-2 | 2A-0201314 |
| Ethyl(1R,2S)-2-(4-Fluorobenzylamino)cyclopentanecarboxylate | 1033756-46-5 | 2A-9086561 |
| Ethyl(1S,2R)-2-Aminocyclopentanecarboxylate | 197904-11-3 | 2A-9086562 |
| Browse all Pharmaceutical Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS